{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-296686","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2022-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.584856+00:00","generated_at":"2026-06-21T10:55:47.726210+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Intellia raises ~$293.5M in public offering of 6.55M shares at $45.80","bullets":["Offering of 6,550,219 shares of common stock at $45.80 per share; underwriter option for up to 982,532 additional shares.","Net proceeds estimated at $293.5M after underwriting discount and expenses; expected close December 2, 2022.","Underwriting agreement with Goldman Sachs & Co. LLC; customary representations and indemnification provisions.","Offering conducted under existing shelf registration statement (File No. 333-251022); prospectus supplement dated November 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-296686","json":"https://secwatch.observer/filing/0001193125-22-296686.json","markdown":"https://secwatch.observer/filing/0001193125-22-296686.md","text":"https://secwatch.observer/filing/0001193125-22-296686.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312522296686/0001193125-22-296686-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312522296686/d358556d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:55:47.726210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03e26248726e581b5533eda3558b12dcaa78393b","claim":"Intellia Therapeutics, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC valued at approximately $293.5 million (effective 2022-11-30).","evidence_excerpt":"On November 30, 2022, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC (the “Underwriter”), related to a public offering (the “Offering”) of 6,550,219 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $45.80 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312522296686/0001193125-22-296686-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC"},{"label":"Value","value":"approximately $293.5 million"},{"label":"Effective","value":"2022-11-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}